Impact of Diets on Response to Immune Checkpoint Inhibitors (ICIs) Therapy against Tumors. 2022

Xin Zhang, and Huiqin Li, and Xiupeng Lv, and Li Hu, and Wen Li, and Meiting Zi, and Yonghan He
Department of Clinical Nutrition, The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China.

Immunotherapy has revolutionized the established therapeutics against tumors. As the major immunotherapy approach, immune checkpoint inhibitors (ICIs) achieved remarkable success in the treatment of malignancies. However, the clinical gains are far from universal and durable, because of the primary and secondary resistance of tumors to the therapy, or side effects induced by ICIs. There is an urgent need to find safe combinatorial strategies that enhance the response of ICIs for tumor treatment. Diets have an excellent safety profile and have been shown to play pleiotropic roles in tumor prevention, growth, invasion, and metastasis. Accumulating evidence suggests that dietary regimens bolster not only the tolerability but also the efficacy of tumor immunotherapy. In this review, we discussed the mechanisms by which tumor cells evade immune surveillance, focusing on describing the intrinsic and extrinsic mechanisms of resistance to ICIs. We also summarized the impacts of different diets and/or nutrients on the response to ICIs therapy. Combinatory treatments of ICIs therapy with optimized diet regimens own great potential to enhance the efficacy and durable response of ICIs against tumors, which should be routinely considered in clinical settings.

UI MeSH Term Description Entries

Related Publications

Xin Zhang, and Huiqin Li, and Xiupeng Lv, and Li Hu, and Wen Li, and Meiting Zi, and Yonghan He
January 2020, Advances in experimental medicine and biology,
Xin Zhang, and Huiqin Li, and Xiupeng Lv, and Li Hu, and Wen Li, and Meiting Zi, and Yonghan He
January 2022, Cancer cell international,
Xin Zhang, and Huiqin Li, and Xiupeng Lv, and Li Hu, and Wen Li, and Meiting Zi, and Yonghan He
May 2020, Neuromuscular disorders : NMD,
Xin Zhang, and Huiqin Li, and Xiupeng Lv, and Li Hu, and Wen Li, and Meiting Zi, and Yonghan He
May 2023, Annales d'endocrinologie,
Xin Zhang, and Huiqin Li, and Xiupeng Lv, and Li Hu, and Wen Li, and Meiting Zi, and Yonghan He
April 2021, Radiology,
Xin Zhang, and Huiqin Li, and Xiupeng Lv, and Li Hu, and Wen Li, and Meiting Zi, and Yonghan He
March 2023, Translational cancer research,
Xin Zhang, and Huiqin Li, and Xiupeng Lv, and Li Hu, and Wen Li, and Meiting Zi, and Yonghan He
October 2022, Biomedicines,
Xin Zhang, and Huiqin Li, and Xiupeng Lv, and Li Hu, and Wen Li, and Meiting Zi, and Yonghan He
June 2020, Cancer immunology, immunotherapy : CII,
Xin Zhang, and Huiqin Li, and Xiupeng Lv, and Li Hu, and Wen Li, and Meiting Zi, and Yonghan He
January 2018, Journal of UOEH,
Xin Zhang, and Huiqin Li, and Xiupeng Lv, and Li Hu, and Wen Li, and Meiting Zi, and Yonghan He
April 2022, Cell communication and signaling : CCS,
Copied contents to your clipboard!